Review
Medicine, General & Internal
Ying Cheng, Hui Li, Liang Zhang, Jing-Jing Liu, Chang-Liang Yang, Shuang Zhang
Summary: In recent years, immune checkpoint inhibitors have made significant breakthroughs in the treatment of lung cancer, with combination immunotherapy being widely used to improve efficacy. The combination of PD-1/PD-L1 inhibitors with other treatment modalities is a current research focus.
CHINESE MEDICAL JOURNAL
(2021)
Article
Oncology
Zaishang Li, Xueying Li, Wayne Lam, Yabing Cao, Hui Han, Xueqi Zhang, Jiequn Fang, Kefeng Xiao, Fangjian Zhou
Summary: Comparing anti-PD-1 and anti-PD-L1 therapies in platinum-resistant UC patients reveals that anti-PD-1 therapy exhibits better antitumor activity, with comparable safety profiles and survival outcomes. This systematic comparison may enhance treatment awareness in this patient population.
FRONTIERS IN ONCOLOGY
(2021)
Review
Medicine, General & Internal
Chu-Ling Li, Yong Song
Summary: Immunotherapy has greatly impacted the treatment of non-small cell lung cancer, with combination strategies showing promising clinical outcomes. However, there is still room for improvement in response rates, necessitating exploration of alternative combination models and candidate selection strategies.
CHINESE MEDICAL JOURNAL
(2021)
Review
Oncology
Chen Zhang, Qing Yang
Summary: Our meta-analysis of 55 studies found that high PD-L1 expression is not significantly associated with overall survival, progression-free survival, recurrence-free survival, cancer-specific survival, and disease-free survival in gynecological cancers. However, subgroup analysis revealed that high PD-L1 expression may be correlated with a shorter overall survival in some cases. Additionally, PD-L1 positivity was associated with certain clinical parameters and could potentially predict response to anti-PD-1/PD-L1 treatment.
FRONTIERS IN ONCOLOGY
(2021)
Review
Immunology
Lin Zhang, Bo Hao, Zhihua Geng, Qing Geng
Summary: Toripalimab, a selective anti-PD-1 monoclonal antibody, has shown anti-tumor effects in melanoma, nasopharyngeal carcinoma, and urothelial carcinoma, and could be a valuable choice for future tumor treatment decision-making.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Pharmacology & Pharmacy
Taisuke Kaiho, Hidemi Suzuki, Atsushi Hata, Hiroki Matsumoto, Kazuhisa Tanaka, Yuichi Sakairi, Shinichiro Motohashi, Ichiro Yoshino
Summary: Immune checkpoint molecules, such as PD-1 and PD-L1, have been shown to be important in lung cancer treatment. This study explored the role of these proteins in acute rejection in a mouse model of tracheal transplantation and found that PD-L1 Fc recombinant protein could decrease inflammatory cytokines and reduce the proportion of CD4+ T cells, suggesting a potential novel target for immunotherapy in lung transplantation.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Oncology
Adriana Hepner, Victoria G. Atkinson, James Larkin, Rebecca A. Burrell, Matteo S. Carlino, Douglas B. Johnson, Lisa Zimmer, Katy K. Tsai, Oliver Klein, Serigne N. Lo, Andrew Haydon, Prachi Bhave, Megan Lyle, Lalit Pallan, Ines Pires da Silva, Camille Gerard, Olivier Michielin, Georgina V. Long, Alexander M. Menzies
Summary: This study retrospectively analyzed the efficacy and safety of ipilimumab re-induction in patients with advanced melanoma who developed acquired resistance after combination immunotherapy. The response rate to reinduction therapy was 26%, with a disease control rate of 45%. Clinicians should be cautious of immune-related adverse events, including the recurrence of events observed during induction therapy.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
David A. Reardon, Tae Min Kim, Jean-Sebastien Frenel, Matteo Simonelli, Juanita Lopez, Deepa S. Subramaniam, Lillian L. Siu, Hui Wang, Suba Krishnan, Karen Stein, Christophe Massard
Summary: Pembrolizumab monotherapy showed durable antitumor activity in a subset of patients with recurrent glioblastoma, with an overall response rate of 8%. Treatment-related adverse events were common, but manageable. Future studies on combination regimens may further improve outcomes.
Article
Immunology
Baoshan Wang, Dazhou Li, Dehua Zeng, Wen Wang, Chuanshen Jiang
Summary: We report a rare case of a middle-aged woman with progressive upper abdominal pain and melena. Laboratory testing showed elevated level of carcinoembryonic antigen. Imaging and cytologic studies excluded metastasis and confirmed primary periampullary squamous cell carcinoma. The tumor had high expression of programmed cell death-ligand 1 (PD-L1), and the patient responded well to chemotherapy combined with immunotherapy.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Oncology
Chia-Jung Li, Li-Te Lin, Ming-Feng Hou, Pei-Yi Chu
Summary: Significant progress has been made in understanding the role of PD-L1 in breast cancer, especially in TNBC. Early clinical trials of PD-L1/PD-1 inhibitors have shown efficacy in refractory metastatic breast cancer patients, particularly in TNBC. Mechanisms and factors influencing the immunoediting process have been summarized and analyzed in detail.
Review
Oncology
Liza C. Villaruz, George R. Blumenschein Jr, Gregory A. Otterson, Ticiana A. Leal
Summary: The development of PD-1/PD-L1 immune checkpoint inhibitors has revolutionized the treatment of advanced and/or metastatic NSCLC. However, many patients do not respond or only have a temporary benefit from these agents. Resistance mechanisms, such as upregulation of immune checkpoints and immunosuppressive tumor microenvironment, need to be overcome to improve patient outcomes. This review discusses novel therapeutic strategies to enhance responses to PD-(L)1 inhibitors and counter resistance in NSCLC, and summarizes the latest clinical evidence.
Article
Oncology
Arun Rajan, Jhanelle E. Gray, Siddhartha Devarakonda, Ruemu Birhiray, Borys Korchin, Erika Menius, Renee N. Donahue, Jeffrey Schlom, James L. Gulley
Summary: CV301 in combination with PD-1 inhibitors is safe and clinically active in advanced NSCLC patients, without an increased frequency or severity of immune-related adverse events.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Oncology
Gerd Jomrich, Dagmar Kollmann, Dariga Ramazanova, Robin Ristl, Richard P. Grose, Ayseguel Ilhan-Mutlu, Matthias Preusser, Christina Fassnacht, Yi-Chien Tsai, Emmanuella Guenova, Sebastian F. Schoppmann
Summary: This study investigated the impact of neoadjuvant chemotherapy on the expression of PD-1 and PD-L1 in adenocarcinomas of the gastroesophageal junction. The results showed a significant increase in PD-1 expression and a decrease in PD-L1 expression after neoadjuvant therapy. These findings suggest that the combined use of cytotoxic chemotherapy and PD-1 axis blockade may be beneficial for patients with adenocarcinomas of the gastroesophageal junction.
Article
Chemistry, Multidisciplinary
Yu Liu, Zaigang Zhou, Jiting Hou, Wei Xiong, Heejeong Kim, Jiashe Chen, Chunjuan Zheng, Xin Jiang, Juyoung Yoon, Jianliang Shen
Summary: In this study, a new PD-L1 regulation strategy was developed by selectively down-regulating PD-L1 expression in tumors using mitochondria-targeted IR-LND@Alb nanoparticles. The anti-tumor efficacy of this strategy was found to be superior to conventional anti-PD-L1 monoclonal antibodies. Interestingly, IR-LND also showed potential as a novel photodynamic therapy (PDT) drug with self-oxygen and self-PD-L1 regulation capability.
ADVANCED MATERIALS
(2022)
Review
Immunology
Quanqing Tang, Shihao Li, Gaozhen Huang, Hongwei Liu
Summary: Urothelial carcinoma (UC) is a common malignant tumor. Platinum-based chemotherapy has been the standard treatment for metastatic UC, but immune checkpoint inhibitors (ICIs) offer hope for patients unfit for platinum therapy.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Biochemical Research Methods
Erik H. L. P. G. Huys, Willemijn Hobo, Frank W. M. B. Preijers
Summary: The 10-color panel with 21 monoclonal antibodies is designed for fast and comprehensive screening of leukemia and lymphoma cells in all hematopoietic cell lineages. By stacking conjugates in one color due to limited PMTs, it enables simultaneous analysis of aberrant cells and improves the diagnostic potential for hematological malignancies.
Article
Medical Laboratory Technology
Vincent H. J. van der Velden, Frank Preijers, Ulrika Johansson, Theresia M. Westers, Alan Dunlop, Anna Porwit, Marie C. Bene, Peter Valent, Jeroen te Marvelde, Orianne Wagner-Ballon, Uta Oelschlaegel, Leonie Saft, Sharham Kordasti, Robin Ireland, Eline Cremers, Canan Alhan, Carolien Duetz, Willemijn Hobo, Nicolas Chapuis, Michaela Fontenay, Peter Bettelheim, Lisa Eidenshink-Brodersen, Patricia Font, Michael R. Loken, Sergio Matarraz, Kiyoyuki Ogata, Alberto Orfao, Katherina Psarra, Dolores Subira, Denise A. Wells, Matteo G. Della Porta, Kate Burbury, Frauke Bellos, Elisabeth Weiss, Wolfgang Kern, Arjan van de Loosdrecht
Summary: This article reviews the progress of flow cytometry (FCM) in the diagnosis of myelodysplastic syndrome (MDS) in recent years, and provides optimal methods and recommendations for sample processing, antibody panels and fluorochromes, and current hardware technologies. These recommendations will facilitate the appropriate application of FCM assays in the diagnostic workup of MDS patients, but further standardization and harmonization are needed.
CYTOMETRY PART B-CLINICAL CYTOMETRY
(2023)
Article
Medical Laboratory Technology
Arjan A. Loosdrecht, Wolfgang Kern, Anna Porwit, Peter Valent, Sharham Kordasti, Eline Cremers, Canan Alhan, Carolien Duetz, Alan Dunlop, Willemijn Hobo, Frank Preijers, Orianne Wagner-Ballon, Nicolas Chapuis, Michaela Fontenay, Peter Bettelheim, Lisa Eidenschink-Brodersen, Patricia Font, Ulrika Johansson, Michael R. Loken, Jeroen G. Marvelde, Sergio Matarraz, Kiyoyuki Ogata, Uta Oelschlaegel, Alberto Orfao, Katherina Psarra, Dolores Subira, Denise A. Wells, Marie C. Bene, Matteo G. Della Porta, Kate Burbury, Frauke Bellos, Vincent H. J. van der Velden, Theresia M. Westers, Leonie Saft, Robin Ireland
Summary: This article discusses the rationale for including flow cytometry (FCM) in the diagnostic investigation and evaluation of cytopenias and suspected myelodysplastic syndromes (MDS) by the European LeukemiaNet international MDS Flow Working Group. The WHO 2016 classification acknowledges the contribution of FCM in the diagnosis of MDS and its potential usefulness in prognostication, prediction, therapy evaluation, and patient follow-up.
CYTOMETRY PART B-CLINICAL CYTOMETRY
(2023)
Article
Immunology
Maarten Versteven, Donovan Flumens, Diana Campillo-Davo, Hans De Reu, Laura Van Bruggen, Stefanie Peeters, Viggo Van Tendeloo, Zwi Berneman, Harry Dolstra, Sebastien Anguille, Willemijn Hobo, Evelien Smits, Eva Lion
Summary: Dendritic cell (DC) vaccines have shown promise in cancer immune therapy, but further optimization is needed to improve their clinical responses. Silencing PD-L1 and PD-L2 can enhance the stimulatory potential of DC vaccines and improve the efficacy of anti-tumor immunity.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Oncology
Raquel S. Laureano, Jenny Sprooten, Isaure Vanmeerbeerk, Daniel M. Borras, Jannes Govaerts, Stefan Naulaerts, Zwi N. Berneman, Benoit Beuselinck, Kalijn F. Bol, Jannie Borst, An Coosemans, Angeliki Datsi, Jitka Faucikova, Lisa Kinget, Bart Neyns, Gerty Schreibelt, Evelien Smits, Rudiger Sorg, Radek Spisek, Kris Thielemans, Sandra Tuyaerts, Steven De Vleeschouwer, I. Jolanda M. de Vries, Yanling Xiao, Abhishek D. Garg
Summary: DC-based vaccination for cancer treatment has advanced significantly over recent decades, but still shows suboptimal anti-tumor efficacy in the clinic. Current efforts are focused on improving the immunogenicity and efficacy of DC vaccines in oncology.
Review
Oncology
Jo Raskin, Annemiek Snoeckx, Annelies Janssens, Charlotte De Bondt, Reinier Wener, Mick van de Wiel, Jan P. van Meerbeeck, Evelien Smits
Summary: This paper highlights the importance of considering sex as a significant factor in modern thoracic oncology practice. It discusses the differences between males and females in lung cancer demographics, immune system responses, presence of oncogenic drivers, and response to targeted therapies. The paper also emphasizes the need for targeted smoking cessation campaigns for women and the importance of including women in lung cancer screening trials.
Article
Pathology
Leonie Kroeze, B. Scheijen, K. M. Hebeda, J. Rijntjes, J. A. C. W. Luijks, D. Evers, W. Hobo, P. J. T. A. Groenen, M. van den Brand
Summary: Clonality assessment by detecting immunoglobulin gene rearrangements is important for determining the clonal relationship between concurrent or subsequent lymphoid malignancies. This study used next generation sequencing to analyze clonality and mutation in a patient diagnosed with B-cell acute lymphoblastic leukemia followed by histiocytic sarcoma. The results showed the evolution of multiple subclones, with one subclone acquiring a RAF1 mutation and evolving into histiocytic sarcoma.
Article
Oncology
Yana Debie, Jonas R. M. Van Audenaerde, Timon Vandamme, Lieselot Croes, Laure-Anne Teuwen, Lise Verbruggen, Greetje Vanhoutte, Elly Marcq, Lisa Verheggen, Debbie Le Blon, Bart Peeters, Maria E. Goossens, Pieter Pannus, Kevin K. Arien, Sebastien Anguille, Annelies Janssens, Hans Prenen, Evelien L. J. Smits, Christof Vulsteke, Eva Lion, Marc Peeters, Peter A. van Dam
Summary: Patients with cancer have reduced humoral responses after double-dose COVID-19 vaccination, but their cellular response is comparable to healthy individuals. A third dose of BNT162b2 can boost immune responses in both healthy people and cancer patients. This study compares the effects of a third dose of BNT162b2 after homologous (double-dose BNT162b2) and heterologous (ChAdOx1) vaccination in cancer patients.
CLINICAL CANCER RESEARCH
(2023)
Review
Medical Laboratory Technology
Anna Porwit, Marie C. Bene, Carolien Duetz, Sergio Matarraz, Uta Oelschlaegel, Theresia M. Westers, Orianne Wagner-Ballon, Shahram Kordasti, Peter Valent, Frank Preijers, Canan Alhan, Frauke Bellos, Peter Bettelheim, Kate Burbury, Nicolas Chapuis, Eline Cremers, Matteo G. Della Porta, Alan Dunlop, Lisa Eidenschink-Brodersen, Patricia Font, Michaela Fontenay, Willemijn Hobo, Robin Ireland, Ulrika Johansson, Michael R. Loken, Kiyoyuki Ogata, Alberto Orfao, Katherina Psarra, Leonie Saft, Dolores Subira, Jeroen te Marvelde, Denise A. Wells, Vincent H. J. van der Velden, Wolfgang Kern, Arjan A. van de Loosdrecht
Summary: Multiparameter flow cytometry (MFC) is an essential method in bone marrow investigation for patients with cytopenia and suspected myelodysplastic syndrome (MDS), providing valuable information for diagnosis and treatment follow-up. This document summarizes recommendations from the ELN iMDS Flow on analytical issues in MFC, including the analysis of different cell subsets and the use of specific markers for MDS diagnosis. Machine-learning-based analytical tools and large uniform datasets are suggested for future research to improve integrated diagnostics and risk stratification in MDS.
CYTOMETRY PART B-CLINICAL CYTOMETRY
(2023)
Article
Oncology
Christophe Deben, Edgar Cardenas de la Hoz, Maxim Le Compte, Paul Van Schil, Jeroen M. H. Hendriks, Patrick Lauwers, Suresh Krishan Yogeswaran, Filip Lardon, Patrick Pauwels, Steven Van Laere, Annemie Bogaerts, Evelien Smits, Steve Vanlanduit, Abraham Lin
Summary: A high-throughput and automated live-cell image analysis software called OrBITS was developed for kinetic monitoring of organoids. The software combines computer vision with convolutional network machine learning and was validated against standard assays. Using OrBITS, the drug screening of lung and pancreatic cancer treatments provided further insights into the drugs' mechanism of action.
Review
Pharmacology & Pharmacy
Abraham Lin, Maxime Sahun, Eline Biscop, Hanne Verswyvel, Jorrit De Waele, Joey De Backer, Claudia Theys, Bart Cuypers, Kris Laukens, Wim Vanden Berghe, Evelien Smits, Annemie Bogaerts
Summary: This study aimed to investigate the mechanisms of NTP therapy sensitivity and resistance by using the first-ever NTP-resistant cell line derived from sensitive melanoma cells. The cells were exposed to NTP for 12 weeks and evaluated against the parental control cells. Transcriptome sequencing and metabolic analysis revealed a preference towards aerobic glycolysis and increased vulnerability to lipid peroxidation and ferroptosis in NTP-resistant cells.
DRUG RESISTANCE UPDATES
(2023)
Article
Oncology
Tal Flieswasser, Astrid van den Eynde, Laurie Freire Boullosa, Joeran Melis, Christophe Hermans, Celine Merlin, Ho Wa Lau, Jonas Van Audenaerde, Filip Lardon, Evelien Smits, Patrick Pauwels, Julie Jacobs
Summary: In this study, the cytotoxic and immune stimulatory potential of an anti-CD70 therapy in NSCLC was explored. The results showed that anti-CD70 therapy resulted in NK-mediated killing of NSCLC cells and increased production of pro-inflammatory cytokines by NK cells. Combination of chemotherapy and anti-CD70 therapy further enhanced NSCLC cell killing and improved survival in vivo.
Article
Biochemistry & Molecular Biology
Laurie Freire Boullosa, Jinthe Van Loenhout, Tal Flieswasser, Christophe Hermans, Celine Merlin, Ho Wa Lau, Elly Marcq, Marlies Verschuuren, Winnok H. De Vos, Filip Lardon, Evelien L. J. Smits, Christophe Deben
Summary: The study aims to enhance the efficacy of auranofin (AF) as a cancer treatment by combining it with the PARP inhibitor olaparib (referred to as 'aurola'). High concentrations of AF and olaparib synergistically induced cytotoxicity in NSCLC and PDAC cell lines with low levels of mutant p53 protein. The combination strategy of oxidative stress induction with PARP inhibition could be a promising treatment for mutant p53 cancers.